Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Behind the Approval of Lecanemab: A Decade of Hardship Cannot Dampen Passion
Drug Insights
6 min read
Behind the Approval of Lecanemab: A Decade of Hardship Cannot Dampen Passion
11 July 2023
As the only Alzheimer's drug fully approved by the FDA in the last 20 years, it may genuinely bring a ray of hope to patients plagued by the disease worldwide.
Read →
Overview of the Development Progress of TIGIT Drug Target
Overview of the Development Progress of TIGIT Drug Target
11 July 2023
TIGIT, a major immune checkpoint molecule, is expressed on the surface of T cells and natural killer (NK) cells.
Read →
AbbVie: The Exploration Journey of an Immunology Titan
R&D Pipeline
10 min read
AbbVie: The Exploration Journey of an Immunology Titan
11 July 2023
What led to AbbVie's present success? And what lessons can other pharmaceutical companies learn from its success?
Read →
The Magic Bullets of Cancer Treatment: ADCs and Their Journey from Concept to Clinic
Advanced Tech.
5 min read
The Magic Bullets of Cancer Treatment: ADCs and Their Journey from Concept to Clinic
11 July 2023
Unlike conventional chemotherapy, which can damage healthy cells, ADCs are intended to target and kill tumor cells while sparing healthy cells.
Read →
Bringing KRAS G12C Inhibitors to Market: The Game Is On
Bringing KRAS G12C Inhibitors to Market: The Game Is On
11 July 2023
AZD4747, that shows promise in treating tumors with the KRAS G12C mutation.
Read →
Discussing AstraZeneca's Brain-penetrating KRAS Inhibitor
Drug Insights
8 min read
Discussing AstraZeneca's Brain-penetrating KRAS Inhibitor
10 July 2023
KRAS G12C inhibitors that can penetrate the brain have a differentiated clinical advantage.
Read →
AXS-05 or Ketamine,Which is a better choice for depression?
Hot Spotlight
10 min read
AXS-05 or Ketamine,Which is a better choice for depression?
10 July 2023
For most patients with severe depression, monoamine-targeted first or second-line treatments often cannot achieve sufficient therapeutic effects.
Read →
First Non-Hormonal Targeted Therapy: A New Breakthrough in Menopausal Hot Flashes
Drug Insights
6 min read
First Non-Hormonal Targeted Therapy: A New Breakthrough in Menopausal Hot Flashes
7 July 2023
The world's first non-hormonal targeted drug for the treatment of moderate to severe vasomotor symptoms (VMS) caused by menopause.
Read →
Small Nucleic Acid Drugs: Under the Spotlight, Surging Waves
Advanced Tech.
8 min read
Small Nucleic Acid Drugs: Under the Spotlight, Surging Waves
7 July 2023
What are small nucleic acid drugs, and why are they highly valued by industry giants?
Read →
May 2023 Global Innovative Drug Report
May 2023 Global Innovative Drug Report
7 July 2023
The report offers a comprehensive overview of the latest advancements in the pharmaceutical industry.
Read →
From "Angelic Pharmacy" to "Century-Old Store": Unveiling Merck's Road to Revival
R&D Pipeline
10 min read
From "Angelic Pharmacy" to "Century-Old Store": Unveiling Merck's Road to Revival
5 July 2023
The history of Merck, also known as MSD, can be traced back 354 years to 1668, making it a legendary presence among multinational pharmaceutical companies.
Read →
The First Approved C5a Antibody – Vilobelimab
Drug Insights
4 min read
The First Approved C5a Antibody – Vilobelimab
5 July 2023
Vilobelimab is a monoclonal antibody that targets C5a. It is developed by InflaRx NV for the treatment of COVID-19, pyoderma gangrenosum, anti-neutrophil cytoplasmic antibody-associated vasculitis, recurrent cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma, squamous cell carcinoma, pyoderma gangrenosum with vasculitis, granulomatosis with polyangiitis, and microscopic polyangiitis.
Read →